Alam N H, Hamadani Jena D, Dewan Nahrina, Fuchs George J
ICDDR,B, Centre for Health and Population Research, Dhaka, Bangladesh.
J Pediatr. 2003 Nov;143(5):614-9. doi: 10.1067/S0022-3476(03)00500-6.
Efficacy, development of overhydration, and correction of electrolyte disturbances of severely malnourished children with acute diarrhea using a modified oral rehydration solution for malnourished children (termed ReSoMaL and recommended by the World Health Organization [WHO]) were evaluated and compared with standard WHO-oral rehydration solution (ORS).
Children age 6 to 36 months with severe malnutrition and acute watery diarrhea were randomized to ReSoMaL (n=65) or standard WHO-ORS (n=65). Major outcome measures included the number of children who developed overhydration and the number who corrected hypokalemia.
The numbers of children who developed overhydration were not significantly different (ReSoMaL vs WHO-ORS, 5% vs 12%, P=.2). ReSoMaL corrected basal hypokalemia in a greater proportion of children by 24 hours (36% vs 5%, P=.0006) and 48 hours (46% vs 16%, P=.004) compared with WHO-ORS. More children on ReSoMaL than WHO-ORS remained hyponatremic at 48 hours (29% vs 10%, P=.017). Three children in the ReSoMaL group developed severe hyponatremia by 24 hours, with one experiencing hyponatremic convulsions (serum sodium, 108 mmol/L).
ReSoMaL has a large beneficial effect on potassium status compared with standard ORS. However, ReSoMaL therapy may result in symptomatic hyponatremia and seizures in patients with severe diarrhea.
评估使用一种改良的营养不良儿童口服补液溶液(称为ReSoMaL,由世界卫生组织[WHO]推荐)治疗重度营养不良急性腹泻儿童的疗效、水钠潴留的发生情况以及电解质紊乱的纠正情况,并与标准的WHO口服补液盐(ORS)进行比较。
将6至36个月患有重度营养不良和急性水样腹泻的儿童随机分为ReSoMaL组(n = 65)或标准WHO-ORS组(n = 65)。主要结局指标包括发生水钠潴留的儿童数量以及纠正低钾血症的儿童数量。
发生水钠潴留的儿童数量无显著差异(ReSoMaL组与WHO-ORS组分别为5%和12%,P = 0.2)。与WHO-ORS相比,ReSoMaL在24小时(36%对5%,P = 0.0006)和48小时(46%对16%,P = 0.004)时能使更大比例的儿童纠正基础低钾血症。在48小时时,ReSoMaL组仍处于低钠血症的儿童比WHO-ORS组更多(29%对10%,P = 0.017)。ReSoMaL组有3名儿童在24小时时发生严重低钠血症,其中1名出现低钠血症惊厥(血清钠,108 mmol/L)。
与标准ORS相比,ReSoMaL对钾状态有很大的有益作用。然而,ReSoMaL治疗可能会导致重度腹泻患者出现症状性低钠血症和惊厥。